Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellegy Savvy HIV prevention trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cellegy's Phase III HIV prevention trial of the microbicide Savvy (C31G vaginal gel) has reached 50% enrollment, the firm announces March 3. Cellegy estimates 1,500 women have enrolled in the Ghana-based trial since initiation in March 2004. A second trial is underway in Nigeria; both are slated to complete in late 2006. A third study is being conducted in the U.S. and has enrolled 200 patients. Cellegy claims Savvy is the most advanced microbicide in development for HIV prevention. "Savvy has also shown activity that suggests protection against...herpes simplex virus, chlamydia, trichomonas, gonorrhea and syphilis," the firm notes. Cellegy's Biosyn subsidiary is conducting the Savvy trials...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel